Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Jan 12, 2021

SELL
$15.77 - $19.03 $1,103 - $1,332
-70 Closed
0 $0
Q3 2020

Oct 13, 2020

SELL
$16.59 - $24.79 $16 - $24
-1 Reduced 1.41%
70 $1,000
Q2 2020

Aug 06, 2020

BUY
$16.86 - $23.44 $1,197 - $1,664
71 New
71 $2,000
Q1 2020

Apr 29, 2020

SELL
$14.47 - $27.96 $1,258 - $2,432
-87 Closed
0 $0
Q3 2019

Oct 10, 2019

BUY
$16.91 - $36.27 $1,014 - $2,176
60 Added 222.22%
87 $2,000
Q2 2019

Jul 17, 2019

BUY
$31.0 - $36.3 $124 - $145
4 Added 17.39%
27 $1,000
Q1 2019

Apr 03, 2019

BUY
$31.58 - $46.35 $726 - $1,066
23 New
23 $1,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $231M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Cx Institutional Portfolio

Follow Cx Institutional and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cx Institutional, based on Form 13F filings with the SEC.

News

Stay updated on Cx Institutional with notifications on news.